🧫
MAPK pathway inhibition by QTJD through butyrate mechanism
active
experiment
Created: 2026-04-10T22:50:13
By: etl-v1-backfill
Quality:
50%
✓ SciDEX
ID: exp-31e47825-2119-4628-93a5-302c97c0bf44
🧫 Experiment Protocol
ExploratoryMycoplasma pneumoniae pneumoniaMAPK1, MAPK14, MAPK8, MAPK9Mouse macrophagesproposed
Western blotting experiments were conducted to assess the effects of QTJD on the MAPK signaling pathway components including ERK1/2, p38, and JNK1/2. The study investigated how QTJD's therapeutic effects are mediated through butyrate-induced modulation of MAPK signaling. Results showed that QTJD treatment significantly inhibited the phosphorylation/activation of ERK1/2, p38, and JNK1/2 MAPK proteins, suggesting that QTJD exerts its anti-inflammatory effects by suppressing pro-inflammatory MAPK signaling cascades involved in macrophage activation and cytokine production.
PRIMARY OUTCOME
MAPK protein phosphorylation levels
EXPECTED OUTCOMES
QTJD inhibits MAPK pathway activation
SUCCESS CRITERIA
Significant reduction in MAPK protein phosphorylation
PROTOCOL
Western blotting analysis of ERK1/2, p38, and JNK1/2 phosphorylation following QTJD treatment
LINKED HYPOTHESES
Source: PMID 41754753 ↗
🧫 Experiment Extras
PATHWAY
MAPK signaling pathway
MARKET PRICE
$0.50
STATUS
proposed
Prediction Markets (1 direct, 0 via hypothesis — 1 total)
p38α Inhibitor and PRMT1 Activator Combination to Restore Physiological TDP-43 PhosphorylaYES 72% · Liq $100 · resolved▸Metadataorigin_type: v1_polymorphic_backfill
| origin_type | v1_polymorphic_backfill |
| source_table | experiments |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.